The monocyte monolayer assay, an
MMA
RBCs
incompatible transfusion
rare red blood cells
red blood cell antibodies
serologic method
transfused red blood cell survival
Journal
Immunohematology
ISSN: 0894-203X
Titre abrégé: Immunohematology
Pays: United States
ID NLM: 8806387
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
medline:
7
7
2023
pubmed:
5
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
It has long been a goal of transfusion medicine scientists to predict which patients will make clinically significant antibodies when transfused with donor red blood cells (RBCs). But this goal has yet to be achieved. Not all patients have an adverse response to an RBC transfusion by making an antibody to an RBC antigen, and for patients who do, in most cases, they form antibodies to common antigens for which provision of antigen-negative RBCs is not difficult. However, for patients who make antibodies to many antigens and for patients who make an antibody requiring rare blood that is negative for a high-prevalence antigen, knowing the clinical significance of that patient's antibody is important for effective and timely transfusion. This review of the literature provides information on the monocyte monolayer assays (MMAs) developed to predict the outcome of incompatible RBC transfusion. One of these assays has been used for almost 40 years in the United States to predict the outcome of RBC transfusion in patients with alloantibodies for whom provision of rare RBCs is very difficult. Because all transfusion medicine facilities and blood centers will not likely implement the MMA, it is important that the selection of the referral laboratory be carefully made. The MMA is a proven test in the prediction of incompatible transfusion outcomes in patients with IgG-only antibodies. It has been helpful in decision-making when rare blood components are not available or not available quickly, although decisions on blood transfusion must be made by the physician attending the patient and blood should not be withheld waiting for the MMA result in an urgent situation.
Identifiants
pubmed: 37405851
pii: immunohematology-2023-010
doi: 10.21307/immunohematology-2023-010
doi:
Substances chimiques
Isoantibodies
0
Antigens
0
Immunoglobulin G
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-69Informations de copyright
© 2023 S.J.T. Nance, published by Sciendo.
Références
Archer GT. Erythrophagocytosis. Mod Med Aust 1964;7:55.
Archer GT. Phagocytosis by human monocytes of red cells coated with antibodies. Vox Sang 1965;10:590–8.
Cline MJ, Lehrer RI. Phagocytosis by human monocytes. Blood 1968;32:423.
Stevens JO, Schanfield MS, Braley JF. Detection of clinically signifcant IgG antibodies by an in vitro human peritoneal macrophage phagocytosis assay (abstract). Transfusion 1976;16:523.
Schanfeld MS, Bauman D, Stevens JO. The detection of clinically signifcant “low avidity” erythrocyte alloantibodies by human macrophage assay. Transfusion 1978;10:382.
Schanfeld MS, Schoeppner SL, Stevens JO. New approaches to detecting clinically signifcant antibodies in the laboratory. In: Sandler SG, Nusbacher J, Schanfeld MS, Eds. Immunobiology of the erythrocyte. New York: Alan Liss, 1980:305–23.
Hunt JS, Beck ML, Hardman JT, Tegtmeier GE, Bayer WI. Characterization of human erythrocyte alloantibodies by IgG subclass and monocyte interaction. Am J Clin Pathol 198 0;74:259 –6 4.
Hunt JS, Beck ML, Wood GW. Monocyte-mediated erythrocyte destruction: a comparative study of current methods. Transfusion 1981;21:735–8.
Schanfeld MS, Stevens JO, Bauman D. The detection of clinically signifcant erythrocyte alloantibodies using a human mononuclear phagocyte assay. Transfusion 1981;21:571–6.
Schoeppner-Esty S, Wahl T, Zawisza J, Mallory D, Davey R. Stimulation of antibody following transfusion of red cells during 51 chromium survival studies. Blood 1986;68:302a.
Schoeppner-Esty S, Chin J, Mallory D, Davey R. A comparison of the monocyte monolayer (MMA) to the 51 chromium red cell survival for determining the clinical signifcance of red cell alloantibodies. Blood 1986;68:302a.
Eckrich RJ, Mallory DM, Sandler SG. Correlation of monocyte monolayer assays and posttransfusion survival of Yt(a+) red cells in patients with anti-Yt a . Immunohematology 1995;11: 81–4.
Byrne PC, Eckrich RJ, Malamut DC, Mallory DM, Sandler SG. Use of the monocyte monolayer assay (MMA) to predict the clinical signifcance of anti-Cr a (abstract). Transfusion 1995;35:61S.
Garratty G. Predicting the clinical signifcance of alloantibodies and determining the in vivo survival of transfused red cells. In: Judd WJ, Barnes A, Eds. Clinical and serologic aspects of transfusion reactions. Arlington, VA: AABB, 1982:91–119.
Garratty G, Nance S, O’Neill P. Correlation of monocyte monolayer assays and RBC survival in patients with allo-antibodies of questionable clinical signifcance. Transfusion 198 5;2 5:474.
Garratty G, Nance S, O’Neill P. Factors that afect interpretation of monocyte monolayer assays. Transfusion 1986;26:570.
Nance S, Arndt P, Garratty G. Predicting the signifcance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;27:4 49–52.
Nance SJ, Arndt PA, Garratty G. The efect of fresh serum on monocyte monolayer reactivity. Transfusion 1988;28:398–9.
Levy GJ, Selset G, McQuiston D, et al. Clinical signifcance of anti-Yt b : report of a case using a 51 chromium red cell survival study. Transfusion 1988;28:265–7.
Garratty G. Predicting the clinical signifcance of red cell antibodies with in vitro cellular assays. Trans Med Rev 1990;4:297–312.
Nance S. Review: measuring red cell survival and determining the clinical signifcance of red cell antibodies. Immunohematology 1995;11:31–8.
Lucas GF, Hadley SG, Nance SJ, Garratty G. Predicting hemolytic disease of the newborn: a comparison of the monocyte monolayer assay and the chemiluminescence test. Transfusion 1993;33:484–7.
Nance S, Nelson J, O’Neill P, Garratty G. Correlation of monocyte monolayer assays, maternal antibody titers, and clinical course in hemolytic disease of the newborn (HDN) (abstract). Transfusion 1984;24:415.
Nance S, Nelson J, Horenstein J, O’Neill P, Garratty G. Predictive value of amniocentesis versus monocyte monolayer assays in pregnant women with Rh antibodies (abstract). Transfusion 1986;26:570.
Nance SJ, Nelson JM, Horenstein J, Amdt PA, Platt LD, Garratty G. Monocyte monolayer assay: an efcient noninvasive technique for predicting the severity of hemolytic disease of the newborn. Am J Clin Pathol 1989;92:89–92.
Mollison PL. Results of tests with diferent cellular bioassays in relation to severity of RhD haemolytic disease: report from nine collaborating laboratories. Vox Sang 1991;60:225–9.
Hadley AG, Kumpel BM, Leader KA, Poole GD, Fraser ID. Correlation of serological, quantitative and cell-mediated functional assays of maternal alloantibodies with the severity of haemolytic disease of the newborn. Br J Haematol 1991;77:221–8.
Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical signifcance of blood group alloantibodies. Transfusion 2004;44:1273–81.
Nance SJ, Arndt P. What to do when all RBCs are incompatible: serological aspects. Immunohematology 2004;3:147–60.
Church A, Mallory D, Kavitsky D, Nance S. Impact of complement in the monocyte monolayer assay (abstract). Transfusion 1997;37(Suppl):27S.
Maurer J, Kavitsky DM, Meny G, Nance S. Monocyte monolayer assay (MMA) to predict clinical signifcance of RBC alloantibodies: an update. Transfusion 2011;51(Suppl):171A.
Keller MA, Nickle P, Mansfeld P, et al. Use of monocyte monolayer assay in a patient with anti-hr S and -Hr. Transfusion 2017;57(S 3) : 3 6 A.
Nance S. A review of the in vitro methods to predict the clinical signifcance of red cell alloantibodies. Immunohematology 2018;34:11–5.
Maurer J, Nance S, Nickle P. Relationship of antibody reactivity strength to reactivity in the monocyte monolayer assay (MMA). Transfusion 2018;58:187A.
Maurer J, Nance S, Nickle P. Monocyte monolayer assay (MMA) to predict clinical signifcance of alloantibodies: a 22 year review. Transfusion 2018;58:103A.
Flickinger C. In search of red blood cells for alloimmunized patients with sickle cell disease. Immunohematology 2006;22:136–42.
Nance S, Scharberg EA, Thornton N, Yahalom V, Lomas-Francis C. International rare donor panels: a review. Vox Sang 2016;110:209–18.
Seltsam A, Wagner FF, Salama A, et al. Antibodies to high frequency antigens may decrease the quality of transfusion support: an observational study. Transfusion 2003;43:1563–6.
Branch DR, Gallagher MT, Mison AP, Sy Siok Hian AL, Petz LD. In vitro determination of red cell alloantibody signifcance using an assay of monocyte-macrophage interaction with sensitized erythrocytes. Br J Haematol 1984;56:19–29.
Branch DR, Gallagher MT. Correlation of in vivo alloantibody signifcance or insignifcance with an in vitro monocyte-macrophage phagocytosis assay. Br J Haematol 1986;62: 783–5.
Branch DR, Gallagher MT. Red blood cell mononuclear phagocyte assay. Vox Sang 1985;48:323–4.
Branch DR, Gallagher MT. The importance of CO 2 in short-term monocyte-macrophage assays. Transfusion 1985;25: 399–400.
Tong TK, Cen S, Branch DR. The monocyte monolayer assay: past, present and future. Transfus Med Rev 2019;33:24–8.
Kipkeu BJ, Shyian ML, da Silveira Cavalcante L, et al. Evaluation of the functional properties of cryopreserved bufy coat–derived monocytes for monocyte monolayer assay. Transfusion 2018;58:2027–35.
Brojer E, Zupanska B, Michalewaks B. Adherence to human monocytes of red cells from autoimmune haemolytic anaemia and red cells sensitized with alloantibodies. Haematologia (Budap) 1982;15:135–45.
Zupanska B, Thompson E, Brojer E, Merry AH. Phagocytosis of erythrocytes sensitized with known amounts of IgG1 and IgG3 anti-Rh antibodies. Vox Sang 1987;53:96–101.
Zupanska B, Brojer E, Richards Y, Lenkiewicz B, Seyfried H, Howell P. Serological and Immunological characteristics of maternal anti-Rh(D) antibodies in predicting severity of haemolytic disease of the newborn. Vox Sang 1989;56:247–53.
Zupanska B, Brojer E, McIntosh J, Seyfried H, Howell P. Correlation of monocyte-monolayer assay results, number of erythrocyte-bound IgG molecules, and IgG subclass composition in the study of red cell alloantibodies other than D. Vox Sang 1990;58:276–80.
Zupanska B, Gronkowska A, Zimeski M. Comparison of activity of peripheral monocytes and splenic macrophages in the monocyte monolayer assay. Vox Sang 1995;68:241–2.
Zupanska B. Assays to predict the clinical signifcance of blood group antibodies. Curr Opin Hematol 1998;5:412–6.
Baldwin ML, Ness PM, Barrasso C, et al. In vivo studies of the long-term 51 Cr red cell survival of serologically incompatible red cell units. Transfusion 1985;25:34–8.
Wren MR, Issitt PD. The monocyte monolayer assay and in vivo antibody activity (abstract). Transfusion 1986;26:548.
Issitt PD, Gutgsell NS, Hervis L. Some stored antibodies give unreliable results in the monocyte monolayer assay. Transfusion 1988;28:399–400.
Gutgsell NS, Issitt LA, Issitt PD. Transfusion of antigen-positive, serologically-incompatible blood in immunized patients, based solely on the results of a monocyte monolayer assay (MMA) (abstract). Transfusion 1988;28:32S.
Fabron A Jr, Baleotti W Jr, de Mello AB, et al. Application of noninvasive phagocytic cellular assays using autologous monocytes to assess red cell alloantibodies in sickle cell patients. Transfus Apher Sci 2004;31:29–35.
Noumsi GT, Billingsley KL, Moulds JM. Successful transfusion of antigen positive blood to alloimmunised patients using a monocyte monolayer assay. Transfus Med 2015;25:92–100.
El-sayed HAN, Abdollah MRA, Raafat SN, Ragab D. Monocyte monolayer assay in pre-transfusion testing: a magic key in transfusing patients with recurrent bad cross-match due to alloimmunization. J Immunol Methods 2021;492:112968.
Bromilow IM, Duguid JK. Monocyte monolayer assay, autoanalyser values, and haemolytic disease of the newborn (letter). Br J Haematol 1991;78:588.
Brown SJ, Perkins JT, Sosler SD, Hesketh D, Moise KJ. The monocyte-monolayer assay does not predict severity of hemolytic disease of the newborn (abstract). Transfusion 1991;31(Suppl):53S.
Balola AHA, Mayer B, Bartolmäs T, Salama A. A fuorometric erythrophagocytosis assay using diferentiated monocytic THP-1 cells to assess the clinical signifcance of antibodies to red blood cells. Vox Sang 2021;116:1106–16.
Nance S, Scandone P, Fassl L, et al. Monocyte monolayer assay (MMA) results are afected by transfusion of incompatible red cells (abstract). Transfusion 1997;37(Suppl):37S.
Branch DR, Sandhu G, Raos M. Monocyte monolayer predictions of clinical outcome for serologically incompatible red blood cells is all about timing. Transfusion 2021;61: 2516–7.
Nance S. Optimizing the use of limited rare red cells for hematopoietic cell transplant recipients. Transfusion 2007;47: 75 4 –7.
Garratty G. Advances in red blood cell Immunology 1960 to 2009. Transfusion 2010;50:526–35.
Meny G. Review: transfusing incompatible RBCs: clinical aspects. Immunohematology 2004;20:161–6.